Zoetis Inc. (NYSE:ZTS) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 88.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,028 shares of the company’s stock after selling 157,031 shares during the quarter. SG Americas Securities LLC’s holdings in Zoetis were worth $3,953,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of ZTS. Evermay Wealth Management LLC boosted its holdings in shares of Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares in the last quarter. Worth Asset Management LLC bought a new position in Zoetis in the 1st quarter valued at about $26,000. VisionPoint Advisory Group LLC bought a new position in Zoetis in the 2nd quarter valued at about $29,000. Finally, Moisand Fitzgerald Tamayo LLC grew its position in Zoetis by 105.5% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after buying an additional 96 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,209 shares of company stock valued at $408,453 over the last three months. 0.15% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus increased their target price on shares of Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, January 12th. BNP Paribas assumed coverage on shares of Zoetis in a research report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 target price for the company. Piper Sandler increased their target price on shares of Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, February 20th. Barclays increased their target price on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. Finally, StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $224.33.

Read Our Latest Stock Analysis on Zoetis

Zoetis Price Performance

ZTS stock opened at $168.90 on Monday. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a one year low of $151.03 and a one year high of $201.92. The firm has a market capitalization of $77.33 billion, a PE ratio of 33.31, a P/E/G ratio of 2.58 and a beta of 0.87. The firm has a 50-day moving average of $187.53 and a two-hundred day moving average of $182.62.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $1.15 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.